(Q28279863)

Pharmacotherapy of Adult Attention Deficit/Hyperactivity Disorder

ChEBI release 2020-05-28

1 reference

Alisa K Christman

1

0 references

Joli D Fermo

series ordinal

2

0 references

John S Markowitz

series ordinal

3

0 references

language of work or name

English

0 references

publication date

August 2004

0 references

published in

Pharmacotherapy

0 references

volume

24

0 references

issue

8

0 references

page(s)

1020-36

0 references

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.11.1020.36146

Non-stimulant treatments for ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.11.1020.36146

The norepinephrine transporter gene and attention-deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.11.1020.36146

A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.11.1020.36146

Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.11.1020.36146

Effects of antidepressants on uptake and receptor systems in the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.11.1020.36146

Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.11.1020.36146

Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.11.1020.36146

Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.11.1020.36146

Identification of the human cytochromes P450 responsible for atomoxetine metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.11.1020.36146

Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.11.1020.36146

Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.11.1020.36146

Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.11.1020.36146

Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.11.1020.36146

Atomoxetine Hydrochloride: Clinical Drug-Drug Interaction Prediction and Outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.11.1020.36146

Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.11.1020.36146

Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.11.1020.36146